EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High Eradication Rate of a Potassium‐Competitive Acid Blocker‐Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real‐World Study

Ji-Yan Li iD, Ying-Ying Han, Dong-Yan Li, Jing-Mei Liu, Zhen-Zhen Zhou, Ya-Ni Zhou, Lin Tuo, Xiao-Jiao Yao, Mei Liu, Ge Wang, Pei-Yuan Li iD

Helicobacter · 2026-05 · 31 (3)

DOI: 10.1111/hel.70128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Helicobacter, online erschienen am 16.05.2026. Verfasst von Ji-Yan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Furazolidone, Bismuth, Minocycline. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tongji Hospital Clinical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Management of refractory Helicobacter pylori ( H. pylori ) infection remains challenging due to increasing antibiotic resistance and limited effective rescue options. Minocycline and furazolidone retain low resistance rates, while potassium‐competitive acid blockers (P‐CABs) provide potent and sustained acid suppression. This study aimed to evaluate the efficacy and safety of a 14‐day P‐CAB‐based regimen combining minocycline, furazolidone, and bismuth in patients with refractory H. pylori infection.

Methods

From January 2023 to October 2025, clinical data were collected from patients with refractory H. pylori infection who received the above regimen at Tongji Hospital, Wuhan, China. Eradication was assessed by a urea breath test performed at least 4 weeks after treatment. Adverse events during treatment were recorded.

Results

A total of 368 patients were included in modified intention‐to‐treat analysis. Of them, 183 (49.7%) had two previous eradication failures, 165 (44.8%) had three to four failures, and 20 (5.4%) had five or more failures. Among the 143 patients who underwent antibiotic resistance gene testing, the resistance rates to clarithromycin and quinolones were 96.5% and 79.7%, respectively. The H. pylori eradication rate was 92.7% (95% CI 89.5%–94.9%) in modified intention‐to‐treat analysis and 96.4% (95% CI 93.8%–97.9%) in per‐protocol analysis. Adverse events occurred in 25.8% of patients and were predominantly mild to moderate, with dizziness (9.5%), nausea (5.2%), and abdominal distension (5.2%) most common. Poor compliance (OR = 18.14, 95% CI 6.39–51.51) and peptic ulcer (OR = 4.34, 95% CI 1.27–14.82) were independently associated with eradication failure.

Conclusions

The 14‐day regimen of P‐CAB, minocycline, furazolidone, and bismuth is highly effective and well tolerated in patients with refractory H. pylori infection. This regimen represents a promising empirical rescue therapy, particularly in settings where antimicrobial susceptibility testing is unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsFurazolidoneBismuthMinocyclineHelicobacter pyloriAnti-Bacterial AgentsHumansFemaleMaleMiddle AgedDrug Therapy, CombinationAdultTreatment OutcomeChinaAgedDrug Resistance, Bacterial

Stichwörter der Autor:innen

P‐CABbismuthfurazolidoneminocyclinerefractory Helicobacter pylori infection

Substanzen

FurazolidoneBismuthMinocyclineAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Division of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Health Management Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Ji-Yan Li, Pei-Yuan Li

Förderung

  • Tongji Hospital Clinical Research Fund

Zitieren

APA

Li, J. Y., Han, Y. Y., Li, D. Y., Liu, J. M., Zhou, Z. Z., Zhou, Y. N., Tuo, L., Yao, X. J., Liu, M., Wang, G., & Li, P. Y. (2026). High Eradication Rate of a Potassium‐Competitive Acid Blocker‐Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real‐World Study. Helicobacter, 31(3). https://doi.org/10.1111/hel.70128

Vancouver

Li JY, Han YY, Li DY, Liu JM, Zhou ZZ, Zhou YN, et al. High Eradication Rate of a Potassium‐Competitive Acid Blocker‐Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real‐World Study. Helicobacter. 2026;31(3). doi:10.1111/hel.70128

BibTeX
@article{Li2026,
  author = {Li, Ji-Yan and Han, Ying-Ying and Li, Dong-Yan and Liu, Jing-Mei and Zhou, Zhen-Zhen and Zhou, Ya-Ni and Tuo, Lin and Yao, Xiao-Jiao and Liu, Mei and Wang, Ge and Li, Pei-Yuan},
  title = {High Eradication Rate of a Potassium‐Competitive Acid Blocker‐Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real‐World Study},
  journal = {Helicobacter},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.1111/hel.70128}
}
Kostenlos starten →